Raymond James analyst Andrew Cooper lowered the firm’s price target on Myriad Genetics (MYGN) to $19 from $27 and keeps an Outperform rating on the shares. Myriad’s Q4 print aligned with the ...
(RTTNews) - Myriad Genetics, Inc. (MYGN) Monday announced the appointment of Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback